How to Taper Off Prednisone Safely: Step-by-Step Guide
TL;DR
- Never stop prednisone abruptly after more than 3 weeks of use — a gradual taper is essential to allow your adrenal glands to recover.
- The speed of tapering depends on the starting dose, duration of therapy, and the condition being treated.
- Common steroid withdrawal symptoms include fatigue, joint pain, and nausea — these are distinct from a disease flare and usually resolve within days to weeks.
- A morning cortisol test can confirm whether your adrenal function has recovered before stopping the final dose.
- Always taper under medical supervision. Self-adjusting steroid doses can trigger adrenal crisis, a medical emergency.
Why You Cannot Simply Stop Prednisone
If you have been searching for how to taper prednisone, you likely already sense that stopping cold turkey is risky. Understanding why requires a brief look at how your body handles cortisol — the hormone prednisone replaces.
Your adrenal glands normally produce approximately 5–7 mg of cortisol per day (equivalent to roughly 5 mg of prednisone). When you take exogenous corticosteroids such as prednisone, the hypothalamic-pituitary-adrenal (HPA) axis recognizes that circulating cortisol levels are already high and progressively shuts down its own production. This feedback suppression can begin within days but becomes clinically significant after approximately 3 weeks of continuous use at supraphysiologic doses (generally ≥ 7.5 mg/day of prednisone).
Once suppressed, the HPA axis does not rebound instantly. Recovery can take weeks to months — and in some patients who have been on high-dose steroids for years, up to 12 months or longer. If prednisone is withdrawn too quickly during this window, circulating cortisol drops below the threshold needed for basic physiological functions: maintaining blood pressure, regulating blood glucose, and mounting a stress response. The result can range from vague malaise to life-threatening adrenal crisis (acute adrenal insufficiency).
The Endocrine Society's 2016 clinical practice guideline on primary adrenal insufficiency emphasizes that any patient who has received supraphysiologic glucocorticoid doses for more than 3 weeks should be assumed to have some degree of HPA suppression and should undergo a supervised taper rather than abrupt discontinuation.
Who Needs a Prednisone Taper?
Not every patient who takes prednisone requires a formal taper. The decision depends on dose, duration, and individual risk factors.
| Factor | Taper Likely Needed | Taper May Not Be Needed |
|---|---|---|
| Duration of use | > 3 weeks at any supraphysiologic dose | ≤ 3 weeks (short burst) |
| Dose | ≥ 7.5 mg/day prednisone equivalent | < 5 mg/day (near-physiologic) |
| Dosing schedule | Daily or twice-daily dosing | Alternate-day dosing (less HPA suppression) |
| Time of dosing | Evening dosing (greater suppression) | Morning dosing only |
| Repeated courses | Multiple short courses within 12 months | Single isolated course |
| Cushingoid features | Present (moon face, striae, weight gain) | Absent |
| Underlying disease | Condition likely to flare upon withdrawal | Self-limited condition now resolved |
Key point: Even short courses (5–7 days) at very high doses (e.g., 60 mg/day for acute asthma) generally do not require a formal taper in otherwise healthy adults, according to guidelines from the British Thoracic Society and NICE. However, if the patient has received repeated short bursts — for instance, 3 or more courses in a year — HPA suppression may have accumulated, and a taper should be considered.
Patients with any of the following characteristics warrant particular caution and should always undergo supervised tapering:
- Receiving prednisone ≥ 20 mg/day for more than 3 weeks
- Cushingoid appearance (indicates significant exogenous cortisol exposure)
- Previous difficulty withdrawing from steroids
- Concomitant use of CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) that slow prednisone metabolism and amplify exposure
- Evening dosing schedules, which suppress the natural morning cortisol surge more effectively
Understanding Steroid Withdrawal vs. Disease Flare
One of the most challenging aspects of tapering prednisone — for patients and clinicians alike — is distinguishing between steroid withdrawal syndrome and a flare of the underlying disease. Both can produce overlapping symptoms, but they require opposite responses: withdrawal symptoms call for patience and supportive care, while a true flare may require increasing the dose.
Steroid Withdrawal Symptoms
Withdrawal symptoms result from relative cortisol deficiency as the body adjusts to lower exogenous doses. Common manifestations include:
- Fatigue and lethargy (the most common complaint)
- Myalgia and arthralgia — diffuse muscle and joint aching, often mistaken for a rheumatic flare
- Nausea, anorexia, and weight loss
- Headache
- Low-grade fever
- Mood changes — irritability, emotional lability, or depressed mood
- Dizziness or orthostatic lightheadedness (reflecting early adrenal insufficiency)
These symptoms typically appear within 24–72 hours of a dose reduction and improve over 5–14 days as the body equilibrates at the new dose.
Disease Flare Symptoms
A disease flare, by contrast, reproduces the specific pattern of the original condition. For example, a patient tapering prednisone for rheumatoid arthritis would experience symmetrical joint swelling with morning stiffness — not the vague diffuse achiness of steroid withdrawal. A patient with inflammatory bowel disease would develop bloody diarrhea and abdominal cramping, not simply nausea and fatigue.
| Feature | Steroid Withdrawal | Disease Flare |
|---|---|---|
| Onset after dose reduction | 1–3 days | Days to weeks |
| Character of symptoms | Diffuse, non-specific | Organ-specific, mirrors original disease |
| Fever | Low-grade (< 38.3 °C / 101 °F) | May be higher, with other inflammatory signs |
| Inflammatory markers (CRP, ESR) | Normal or mildly elevated | Significantly elevated |
| Response to holding at current dose | Symptoms resolve in 7–14 days | Symptoms persist or worsen |
| Joint/muscle pain | Generalized, migratory | Localized to previously affected joints |
Practical tip: If symptoms appear after a dose reduction and you are unsure whether it is withdrawal or flare, do not increase the dose immediately. Instead, hold at the current dose for 1–2 weeks. Withdrawal symptoms will typically resolve on their own; a true flare will persist or escalate.
Sample Prednisone Taper Schedules
There is no single universally accepted prednisone taper schedule — the pace must be individualized based on clinical context. However, the following general framework, consistent with Endocrine Society recommendations and widely used in clinical practice, provides a practical starting point.
General Principles
- Taper in steps, not continuously. Reduce the dose, then hold for a period to let the HPA axis adjust before the next reduction.
- Larger decrements at higher doses; smaller decrements at lower doses. At supraphysiologic doses (> 20 mg/day), reductions of 5–10 mg every 1–2 weeks are usually tolerated. Below the physiologic threshold (≈ 5–7.5 mg/day), reductions should be 1 mg — or even 0.5 mg — at a time.
- Morning dosing. Administer the daily dose in the morning to mimic the natural cortisol rhythm and minimize HPA suppression.
- Slow the taper if withdrawal symptoms appear. Go back to the last tolerated dose, hold for 2–4 weeks, then attempt a smaller reduction.
Schedule A — Standard Taper (Starting Dose 40–60 mg/day)
This schedule is appropriate for patients who have been on moderate-to-high-dose prednisone for 4–12 weeks (e.g., for an inflammatory flare).
| Week | Daily Dose (mg) | Reduction Step |
|---|---|---|
| 1–2 | 40 | Starting dose (or current dose) |
| 3–4 | 30 | –10 mg |
| 5–6 | 20 | –10 mg |
| 7–8 | 15 | –5 mg |
| 9–10 | 10 | –5 mg |
| 11–12 | 7.5 | –2.5 mg |
| 13–14 | 5 | –2.5 mg (now at physiologic range) |
| 15–17 | 4 | –1 mg |
| 18–20 | 3 | –1 mg |
| 21–23 | 2 | –1 mg |
| 24–26 | 1 | –1 mg |
| 27 | 0 | Discontinue; check morning cortisol |
Total taper duration: approximately 6 months. This may seem slow, but it prioritizes HPA axis recovery and minimizes the risk of adrenal crisis.
Schedule B — Accelerated Taper (Starting Dose 20–30 mg/day, Duration 3–6 Weeks)
For patients on moderate doses for shorter periods, a faster taper is often feasible.
| Week | Daily Dose (mg) | Reduction Step |
|---|---|---|
| 1 | 20 | Starting dose |
| 2 | 15 | –5 mg |
| 3 | 10 | –5 mg |
| 4 | 7.5 | –2.5 mg |
| 5 | 5 | –2.5 mg |
| 6–7 | 4 | –1 mg |
| 8–9 | 3 | –1 mg |
| 10–11 | 2 | –1 mg |
| 12 | 1 | –1 mg |
| 13 | 0 | Discontinue |
Total taper duration: approximately 3 months.
Schedule C — Slow Taper for Long-Term Use (> 6 Months on ≥ 10 mg/day)
Patients who have been on prednisone for many months or years require the most cautious approach. Below 5 mg/day, reductions of 0.5–1 mg every 2–4 weeks are common, and alternate-day dosing may be introduced to further encourage adrenal recovery.
Below physiologic doses (< 5 mg), many clinicians switch to hydrocortisone (cortisol), which has a shorter half-life and may allow finer dose adjustments (hydrocortisone 20 mg ≈ prednisone 5 mg). This approach is endorsed by several endocrinology centers, though direct comparative trial data are limited.
Monitoring During the Taper: When to Check Cortisol
A critical question during any prednisone taper is: has the HPA axis recovered enough to sustain the patient off exogenous steroids? The primary tool for answering this is the morning serum cortisol.
When to Test
- At physiologic replacement dose (5 mg prednisone or equivalent): Before reducing below this threshold, obtain a morning (8:00 AM) serum cortisol after withholding the previous day's prednisone dose (i.e., measure at a 24-hour trough).
- At 1–2 mg/day or just before discontinuation: Repeat the morning cortisol to confirm recovery.
How to Interpret
- Morning cortisol ≥ 10 µg/dL (275 nmol/L): Suggests adequate basal adrenal function. The taper can generally proceed to discontinuation.
- Morning cortisol 5–10 µg/dL (138–275 nmol/L): Indeterminate — the patient may have partial recovery. A cosyntropin (ACTH) stimulation test can provide further clarity. Continue low-dose replacement and recheck in 4–6 weeks.
- Morning cortisol < 5 µg/dL (138 nmol/L): Indicates ongoing adrenal suppression. The patient should remain on physiologic-dose replacement and be retested after another 4–8 weeks.
The cosyntropin stimulation test (250 µg IV or IM cosyntropin, with cortisol measured at 0 and 30–60 minutes) remains the gold standard for assessing adrenal reserve. A stimulated cortisol ≥ 18 µg/dL (500 nmol/L) is generally considered a normal response, indicating the adrenal glands can mount an appropriate stress response.
The Endocrine Society recommends that patients with indeterminate or low morning cortisol levels who are unable to discontinue steroids should carry medical alert identification and receive stress dose steroids during illness, surgery, or trauma until adrenal recovery is confirmed.
Side Effects of Long-Term Prednisone and How Tapering Helps
Tapering prednisone is not only about avoiding adrenal crisis — it is also the pathway to reducing the cumulative toxicity of long-term glucocorticoid use. Many of the most burdensome side effects are dose- and duration-dependent.
Metabolic effects such as hyperglycemia, weight gain, and dyslipidemia improve progressively as the dose decreases. Patients with steroid-induced diabetes may see glucose control normalize as they reach physiologic doses.
Bone loss (glucocorticoid-induced osteoporosis) is one of the most significant long-term complications. The American College of Rheumatology recommends bone density screening and fracture risk assessment for any patient expected to receive ≥ 2.5 mg/day of prednisone for ≥ 3 months, with initiation of bisphosphonate or other anti-resorptive therapy when indicated. Bone loss begins to stabilize — and may partially reverse — once steroids are discontinued.
Other effects that improve with dose reduction include:
- Skin thinning, easy bruising, and impaired wound healing
- Proximal myopathy (muscle weakness in thighs and upper arms)
- Insomnia and mood disturbances
- Increased infection susceptibility (particularly at doses ≥ 20 mg/day)
- Posterior subcapsular cataracts and elevated intraocular pressure
- Cushingoid redistribution of body fat
Avascular necrosis (osteonecrosis) and certain ophthalmologic complications may not fully reverse after discontinuation and require independent management.
Drug Interactions That Affect Tapering
Several commonly used medications can alter prednisone metabolism and thereby affect the effective speed of your taper. Prednisone is a prodrug converted to its active form, prednisolone, in the liver. Both prednisone and prednisolone are metabolized by the CYP3A4 enzyme system.
| Interacting Drug | Effect on Prednisone | Clinical Implication During Taper |
|---|---|---|
| Ketoconazole, itraconazole | Inhibit CYP3A4 → increased prednisone exposure | May need to reduce prednisone dose further or taper more slowly to avoid excess effect |
| Ritonavir, cobicistat | Strong CYP3A4 inhibition → markedly increased exposure | Cases of iatrogenic Cushing syndrome reported; coordinate taper with HIV specialist |
| Rifampin (rifampicin) | Induces CYP3A4 → decreased prednisone exposure | Effective prednisone levels drop; may precipitate withdrawal symptoms at doses that would otherwise be adequate |
| Phenytoin, carbamazepine, phenobarbital | Induce CYP3A4 → decreased exposure | Similar to rifampin; may require higher maintenance doses and slower taper |
| Oral contraceptives / estrogen | Increase corticosteroid-binding globulin → increased total cortisol (but free cortisol may be unchanged) | Can confound cortisol level interpretation during monitoring |
| NSAIDs (ibuprofen, naproxen) | Additive GI toxicity with corticosteroids | Increased ulcer risk during taper; consider gastroprotection |
Important: If a CYP3A4 inhibitor is started or stopped during a prednisone taper, the effective steroid exposure changes even if the prednisone dose remains the same. Inform your prescriber about any medication changes.
Special Populations
Pregnant and Breastfeeding Patients
Prednisone crosses the placenta, but it is substantially inactivated by placental 11β-hydroxysteroid dehydrogenase, making it one of the preferred corticosteroids during pregnancy when systemic treatment is required. ACOG notes that abrupt discontinuation poses the same adrenal suppression risks in pregnant patients as in the general population. Tapering should follow standard protocols, with awareness that physiologic cortisol production increases during the third trimester.
Prednisone is excreted in breast milk in small amounts. The AAP considers prednisone compatible with breastfeeding at doses ≤ 20 mg/day. At higher doses, waiting 4 hours after dosing before nursing can further reduce infant exposure.
Older Adults
Older adults are particularly vulnerable to glucocorticoid side effects — osteoporotic fractures, hyperglycemia, delirium, and infection. At the same time, HPA axis recovery may be slower in this population. A cautious taper with careful monitoring for both withdrawal symptoms and adverse effects is essential. Bone-protective therapy should be addressed concurrently.
Pediatric Patients
Children on long-term prednisone require careful endocrine follow-up, as HPA suppression can impair growth. The British National Formulary for Children recommends gradual dose reduction with growth monitoring. Pediatric tapers should always be supervised by a specialist.
Patients with Diabetes
Glucocorticoids are potent hyperglycemic agents. As the prednisone dose decreases, insulin or oral hypoglycemic requirements will typically decrease as well. Patients should monitor blood glucose more frequently during the taper to avoid hypoglycemia from now-excessive diabetes medication doses. Coordination between the prescribing clinician and the diabetes care team is essential.
Red Flags — When to Seek Immediate Medical Attention
During a prednisone taper, the following symptoms may indicate acute adrenal insufficiency (adrenal crisis) and require emergency medical care:
- Severe weakness or fatigue that prevents normal activity
- Hypotension — dizziness, lightheadedness, or fainting, especially upon standing
- Nausea, vomiting, or abdominal pain that is persistent or severe
- Unexplained fever — the body cannot mount an adequate stress response without cortisol
- Confusion or altered mental status
- Severe pain (any location) in the setting of recent dose reduction
- Intercurrent illness, injury, or surgery — any significant physiological stress during the taper period requires temporary stress-dose steroids (typically hydrocortisone 50–100 mg IV/IM, followed by 25–50 mg every 8 hours)
Do not wait to see if symptoms improve on their own. Adrenal crisis can progress rapidly to shock and is fatal if untreated. If you cannot reach your prescriber, go to the nearest emergency department and inform the medical team that you are tapering prednisone and may be adrenally suppressed.
Patients in the final stages of tapering (≤ 5 mg/day) or who have recently discontinued prednisone within the past 6–12 months should carry a steroid emergency card or wear a medical alert bracelet indicating their adrenal suppression status.
Frequently Asked Questions
How fast can I taper off prednisone?
The speed depends on your starting dose and how long you have been taking prednisone. Short courses (< 3 weeks) at moderate doses can often be stopped without tapering. Long-term use requires a gradual taper over weeks to months — sometimes up to a year for patients who have been on high doses for extended periods. There is no safe shortcut; rushing the taper risks adrenal crisis.
Can I taper prednisone on my own without a doctor?
No. Self-directed tapering is strongly discouraged. The appropriate pace of tapering depends on clinical factors that require medical assessment, including the reason you are taking prednisone, the risk of disease flare, and whether your adrenal glands have recovered. Your prescriber may also need to order cortisol blood tests at key points in the taper.
What is the lowest dose of prednisone that can still suppress my adrenal glands?
Doses as low as 5 mg/day — the approximate physiologic equivalent of normal cortisol production — can maintain some degree of HPA axis suppression when taken chronically. Even alternate-day dosing does not fully eliminate the risk if continued for many months.
I feel terrible after reducing my dose. Should I go back up?
Not immediately. Mild withdrawal symptoms (fatigue, aching, nausea) are common and usually resolve within 1–2 weeks at the new dose. Hold at your current dose rather than increasing it. If symptoms are severe, persist beyond 2 weeks, or resemble your original disease, contact your prescriber — you may need a smaller dose reduction or further evaluation.
Can I drink alcohol while tapering prednisone?
Moderate alcohol use is not absolutely contraindicated, but both prednisone and alcohol independently irritate the gastric mucosa and raise the risk of GI bleeding. Both also affect blood glucose and mood. During a taper, when your body is already under physiological stress, minimizing alcohol intake is prudent.
Do I need to follow a special diet while tapering?
No specific diet is required, but a few strategies can help manage common steroid side effects during the taper: limiting sodium helps control fluid retention and blood pressure; adequate calcium (1,000–1,200 mg/day) and vitamin D (600–800 IU/day) support bone health; and adequate protein can help counter steroid myopathy. Controlling simple carbohydrate intake helps manage blood glucose fluctuations.
Will I gain weight back after stopping prednisone?
Steroid-related weight gain — driven by increased appetite, fluid retention, and fat redistribution — typically begins to reverse once the dose drops below 7.5–10 mg/day and continues to improve after discontinuation. However, the timeline varies. Some patients notice improvement within weeks; for others, it may take several months for body composition to normalize.
What happens if I need surgery or get seriously ill during the taper?
If you undergo major surgery, sustain significant trauma, or develop a serious illness while your HPA axis is still recovering, you will need stress-dose steroids — a temporary increase in corticosteroid dose to simulate the surge of cortisol your body would normally produce. Standard stress dosing is hydrocortisone 50–100 mg IV every 8 hours on the day of surgery, with rapid taper back to your baseline over 1–3 days. Always inform your surgical and anesthesia team of your steroid history.
References
-
Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364–389. PMID: 26760044
-
Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum. 2016;46(1):133–141. PMID: 27105755
-
Broersen LHA, Pereira AM, Jørgensen JOL, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171–2180. PMID: 25844620
-
NICE. Corticosteroids — oral. Clinical Knowledge Summaries. nice.org.uk/cks/topics/corticosteroids-oral/
-
FDA. Prednisone tablets labeling. DailyMed/NLM
-
Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. PMID: 28585373
-
Paragliola PE, Papi G, Pontecorvi A, Corsello SM. Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int J Mol Sci. 2017;18(10):2201. PMID: 29053578
-
Prete A, Yan Q, Al-Tarrah K, et al. The cortisol stress response induced by surgery: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018;89(5):554–567. PMID: 30047158
-
Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am. 2005;34(2):371–384. PMID: 15850848
-
Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24(8):714–720. PMID: 23806261
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in hospital and ambulatory care pharmacy practice. He has counseled thousands of patients on medication management, including complex corticosteroid regimens. As a contributor to PillsCard.com, Dr. Ozarchuk translates evidence-based pharmacotherapy into practical guidance for patients and caregivers worldwide.
Medical Disclaimer
This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The content provided by PillsCard.com should not be used as a substitute for professional medical judgment. Always consult your physician, pharmacist, or other qualified healthcare provider before starting, stopping, or modifying any medication regimen — including corticosteroid tapering. Individual medical decisions must account for your specific health conditions, medications, and clinical circumstances. If you are experiencing symptoms of adrenal insufficiency or any medical emergency, seek immediate medical attention. PillsCard.com and its contributors assume no liability for actions taken based on the information presented herein.